Influence of mucosal and parenteral immunization with a replication- defective mutant of HSV-2 on immune responses and protection from genital challenge

Virology

Volumn 243, Issue 1, 1998, Pages 178-187

  Morrison, Lynda A ^a   Da Costa, Xavier J ^b   Knipe, David M ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; GENITAL TRACT INFECTION; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; INTRANASAL DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VAGINA MUCOSA; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALIA; HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 2; RNA VIRUSES;

EID: 0032579775     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9047     Document Type: Article

References (37)

1. Guide for the Care and Use of Laboratory Animals. 1985;. p. 85-23.
2. Ashley R., Wald A., Corey L. Cervical antibodies in patients with oral herpes simplex virus type 1 (HSV-1) infection: Local anamnestic responses after genital HSV-2 infection. J. Virol. 68:1994a;5284-5286.
3. Ashley R. L., Corey L., Dalessio J., Wilson P., Remington M., Barnum G., Trethewey P. Protein-specific cervical antibody responses to primary genital herpes simplex virus type 2 infections. J. Infect. Dis. 170:1994b;20-26.
4. Bourne N., Milligan G. N., Schleiss M. R., Bernstein D. I., Stanberry L. R. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine. 14:1996;1230-1234.
5. Boursnell M. E. G., Entwisle C., Blakeley D., Roberts C., Duncan I. A., Chisholm S. E., Martin G. M., Jennings R., NiChallanain D., Sobek I., Inglis S. C., McLean C. S. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J. Infect. Dis. 175:1997;16-25.
6. Brubaker J. O., Thompson C. M., Morrison L. A., Knipe D. M., Siber G. R., Finberg R. W. Induction of Th1-associated immune responses to beta-galactosidase expressed by a replication-defective mutant of herpes simplex virus 1. J. Immunol. 157:1996;1598-1604.
7. Da Costa X. J., Bourne N., Stanberry L. R., Knipe D. M. Construction and characterization of a replication-defective HSV-2. Virology. 232:1997;1-12.
8. Drew M. D., Estrada-Correa A., Underdown B. J., McDermott M. R. Vaccination by cholera toxin conjugated to a herpes simplex virus type 2 glycoprotein D peptide. J. Gen. Virol. 73:1992;2357-2366.
9. Farrell H. E., McLean C. S., Harley C., Efstathiou S., Inglis S., McLean A. C. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J. Virol. 68:1994;927-932.
10. Fujihashi K., Yamamoto M., McGhee J. R., Kiyono H. Alpha beta T cell receptor-positive intraepithelial lymphocytes with CD4+, CD8- and CD4+ phenotypes from orally immunized mice provide Th2-like function for B cell responses. J. Immunol. 151:1993;6681-6691.
11. Gallichan W. S., Rosenthal K. L. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine. 13:1995;1589-1595.
12. Gallichan W. S., Rosenthal K. L. Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract. Virology. 224:1996;487-497.
13. Gao M., Knipe D. M. Genetic evidence for multiple nuclear functions of the herpes simplex virus ICP8 DNA-binding protein. J. Virol. 63:1989;5258-5267.
14. Ghiasi H., Roopenian D. C., Slanina S., Cai S., Nesburn A. B., Wechsler S. L. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge. Immunology. 91:1997;430-435.
15. Haneberg B., Kendall D., Amerongen H. M., Apter F. M., Kraehenbuhl J., Neutra M. R. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect. Immun. 62:1994;15-23.
16. Irie H., Harada Y., Kataoka M., Nagamuta M., Moriya Y., Handa M., Saito M., Matsubara S., Kojima K., Sugawara Y. Efficacy of oral administration of live herpes simplex virus type 1 as a vaccine. J. Virol. 66:1992;2428-2434.
17. Larica P. I., Ejercito M., Kieff E. D., Roizman B. Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J. Gen. Virol. 2:1968;357-364.
18. Matulonis U., Dosiou C., Freeman B., Lamont C., Mauch P., Nadler L. M., Griffin J. D. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: Further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156:1996;1126-1131.
19. McDermott M. R., Smiley J. R., Leslie P., Brais J., Rudzroga H. E., Bienenstock J. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J. Virol. 51:1984;747-753.
20. McDermott M. R., Goldsmith C. H., Rosenthal K. L., Brais L. J. T lymphocytes in genital lymph nodes protect mice from intravaginal infection with herpes simplex virus type 2. J. Infect. Dis. 159:1989;460-466.
21. McDermott M. R., Brais L. J., Evelegh M. J. Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2. J. Gen. Virol. 71:1990;1497-1504.
22. McDermott M. R., Bienenstock J. Evidence for a common mucosal immunologic system 1. Migration of B Immunoblasts into intestinal, respiratory, and genital tissues. J. Immunol. 122:1979;1892-1898.
23. McLean C. S., Erturk M., Jennings R., Ni Challanain D., Minson A. C., Duncan I., Boursnell M. E. G., Inglis S. C. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J. Infect. Dis. 170:1994;1100-1109.
24. McLean C. S., Ni Challanain D., Duncan I., Boursnell M. E. G., Jennings R., Inglis S. C. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine. Vaccine. 14:1996;987-992.
25. Mertz G., Benedetti J., Ashley R., Selke S., Corey L. Risk factors for the sexual transmission of genital herpes. Ann. Intern. Med. 116:1992;197-202.
26. Milligan G., Bernstein D. Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology. 229:1997;259-268.
27. Milligan G. N., Bernstein D. I. Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract. Virology. 206:1995a;234-241.
28. Milligan G. N., Bernstein D. I. Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2. Virology. 212:1995b;481-489.
29. Morrison L. A., Knipe D. M. Immunization with replication-defective mutants of herpes simplex virus type 1: Sites of immune intervention in pathogenesis of challenge virus infection. J. Virol. 68:1994;689-696.
30. Morrison L. A., Knipe D. M. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. Virology. 320:1996;402-413.
31. Morrison L. A., Knipe D. M. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1. Virology. 239:1997;315-326.
32. Nguyen L. H., Knipe D. M., Finberg R. W. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J. Virol. 66:1992;7067-7072.
33. Okahashi N., Yamamoto M., VanCott J. L., Chatfield S. N., Roberts M., Bluethmann H., Hiroi T., Kivono H., McGhee J. R. Oral immunization of interleukin-4 (IL-4) knockout mice with a recombinant Salmonella strain or cholera toxin reveals that CD4+ Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. Infect. Immun. 64:1996;1516-1525.
34. Parr M. B., Kepple L., McDermott M. R., Drew M. D., Bozzola J. J., Parr E. L. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab. Invest. 70:1994;369-380.
35. Tomoda T., Morita H., Kurashige T., Maassab H. F. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: Importance of interferon-gamma production and local IgA response. Vaccine. 13:1995;185-190.
36. VanCott J. L., Staats H. F., Pascual D. W., Roberts M., Chatfield S. N., Yamamoto M., Coste M., Carter P. B., Kiyono H., McGhee J. R. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella. J. Immunol. 156:1996;1504-1514.
37. Zollinger W. D., Boslego J. W. A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies. J. Immunol. Methods. 46:1981;129-140.